R&D | Cutting-edge science and innovative research

News

ASH: AstraZeneca's dual-wielding CAR-T shows promise

AstraZeneca has reported an impressive 96% response rate in the DURGA-1 of BCMAxCD19 CAR-T therapy AZD0120 in heavily pretreated multiple myeloma.

News

Marcio Souza, Praxis' president and chief executive

Praxis soars on rare childhood epilepsy trial data

Praxis looks like it could be filing for approval of two products next year, after its childhood epilepsy drug delivered a win in a pivotal trial.

News

Protego's $130m for amyloidosis drug, and other financings

Our latest crop of biotech financings has nine-figure rounds for Protego and Triana, with Excelsior Sciences and SciNeuro also raising new funds.

R&D

pharmaphorum podcast Episode 224, Sigma Mostafa, KBI Biopharma

CDMOs: Their crucial role and how to select one, with Sigma ...

Sigma Mostafa, CSO at KBI BioPharma, discusses the role of CDMOs and the important factors companies should consider when selecting one.

R&D

Why pharma’s future may run through your local blood centre

With demand for cell and gene therapies (CGTs) growing rapidly, blood centres are indispensable collaborators.

R&D

Biotech’s biggest challenge isn’t scientific, but political ...

News

Sarepta shares slide as DMD treatment woes pile up

The ESSENCE trial of Sarepta's Vyondys 53 and Amondys 45 failed to hit its objective, placing their FDA accelerated approvals at risk.

News

Pfizer files another lawsuit against Metsera, Novo Nordisk

Metsera says Novo Nordisk's takeover offer is superior to one filed by Pfizer, and the latter files a new lawsuit to try to force their deal through.

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/live.png

Webinars

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change.

News

ASH: AstraZeneca's dual-wielding CAR-T shows promise

AstraZeneca has reported an impressive 96% response rate in the DURGA-1 of BCMAxCD19 CAR-T therapy AZD0120 in heavily pretreated multiple myeloma.

News

Praxis soars on rare childhood epilepsy trial data

Praxis looks like it could be filing for approval of two products next year, after its childhood epilepsy drug delivered a win in a pivotal trial.

Press Releases

Views & Analysis

Touring Chiesi's vision for the future at the new Biotech Ce...

Following an invite to fly into Parma, Italy to witness first-hand the press launch of the considerable structure – black-painted and as yet under construction, gigantic cranes and all – th

News

Vir awarded $1 billion multi-year BARDA influenza contract

The US Government’s Biomedical Advanced Research and Development Authority (BARDA) has made an

Views & Analysis

R&D

CDMOs: Their crucial role and how to select one, with Sigma ...

Sigma Mostafa, CSO at KBI BioPharma, discusses the role of CDMOs and the important factors companies should consider when selecting one.

R&D

Why pharma’s future may run through your local blood centre

With demand for cell and gene therapies (CGTs) growing rapidly, blood centres are indispensable collaborators.

R&D

pharmaphorum podcast Episode 223, Shawn Hodges, Revelation Pharma

On US drug shortages and compounding pharmacies, with Shawn ...

Shawn Hodges, CEO of Revelation Pharma, discusses the true state of drug shortages in the US at the moment and the role of compounding pharmacies.

Deep Dive

R&D

R&D Contraceptive pills condoms and intrauterine device

Research and Development

R&D

Deep Dive: Research and Development 2025

Every breakthrough in medicine, every new treatment that changes lives, starts with research.

R&D

A history of vaccination: How immunisation transformed publi...

R&D

Sponsored

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

R&D

evolution of clinical research in the UK

Sponsored

The evolution of clinical research: Embracing new delivery m...

The UK is welcoming a new era of clinical trial delivery, evolving beyond the traditional site-centric approach to also embrace remote, decentralised, virtual, and hybrid trials and enablin

Podcasts

R&D

CDMOs: Their crucial role and how to select one, with Sigma ...

Sigma Mostafa, CSO at KBI BioPharma, discusses the role of CDMOs and the important factors companies should consider when selecting one.

R&D

On US drug shortages and compounding pharmacies, with Shawn ...

Shawn Hodges, CEO of Revelation Pharma, discusses the true state of drug shortages in the US at the moment and the role of compounding pharmacies.

R&D

pharmaphorum podcast Episode 221, Sandeep Kulkarni, Tourmaline Bio

On inflammation, heart health, and GLP-1 possibilities, with...

Sandeep Kulkarni, CEO of Tourmaline Bio, discusses inflammation, & the impact of AI and GLP-1s on cardiology clinical trials and drug development.

Video

R&D

ESMO25: On partnerships between pharma and diagnostic develo...

Jane Li, Senior Director of Pharma CDx and CRO Partnership, Clinical Next Generation Sequencing Business, at Thermo Fisher Scientific discusses CDx.

R&D

Bolstering CAR-T therapies by tackling CRS, with Teresa Whal...

In interview with Teresa Whalen, the CEO of CytoAgents, a clinical-stage drug development company working on a treatment for cytokine release syndrome

R&D

Interview at LSX 25 with Steffen Sebastian Bolz

A different approach to obesity treatment, with Steffen-Seba...

At LSX 2025, editor-in-chief Jonah Comstock connected with Dr Steffen Sebastian-Bolz, chief science officer at Aphaia Pharma.

White Papers

R&D

A man stood on a rock looking towards the horizon

Sponsored

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.

R&D